Joao Morais

List of Publications by Citations

Source: https://exaly.com/author-pdf/8811470/joao-morais-publications-by-citations.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers1,165
citations9
h-index12
g-index12
ext. papers1,356
ext. citations6.9
avg, IF3.38
L-index

#	Paper	IF	Citations
11	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis,	9.5	413
10	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on ThrombosisTask Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1087-107	7	278
9	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1413-25	15.1	211
8	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , 2015 , 131, 1047-53	16.7	59
7	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012 , 14, 681-95	12.3	57
6	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1009-22	7	49
5	The myth of atableacoronary artery disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 9-21	14.8	39
4	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working	7	29
3	Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 164-172 temostasis, 2017, 117, 2215-2236	4.3	7
2	Knowledge and Data Driven Approaches Applied to Clinical Assessment. IFMBE Proceedings, 2018, 133-	136	1
1	Identification of Clinically Relevant Rules: An Interpretable Approach for CVD Risk Assessment. IFMBE Proceedings, 2021, 644-654	0.2	